NICE appoints experienced pharma consultant as Director of NICE Scientific Advice
pharmafile | November 7, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | NICE, government, national institute of health and care excellence, politics, sciences
The National Institute for Health and Care Excellence (NICE) has appointed Jeanette Kusel as Director of NICE Scientific Advice. The Cambridge graduate, an experienced health technology evaluation consultant, will take over from Leeza Osipenko, who has held the position since 2014.
Kusel, who graduated from the University of Cambridge with an undergraduate degree in Natural Sciences in 2008 and MSci in Biochemistry in 2009, began her career as an analyst at the Cambridge-based consultancy Costello Medical in 2009. Having worked in the company for more than nine years Kusel took on roles of increasing seniority while also studying for a second MSc in Health Economics at the University of York between 2010 and 2012.
Kusel later founded the Health Technology Assessment and Health Economics division of Costello Medical while gaining considerable management experience within the company. The experienced consultant later became Scientific Director at Costello Medical in 2016.
Nick Crabb, programme director at NICE commented: “Jeanette brings a wealth of experience and knowledge of the industry and we are excited to welcome her to lead NICE Scientific Advice.”
Kusel added: “I am delighted to be taking up this role at NICE, an organisation I have always had immense respect for. I look forward to supporting the talented NICE Scientific Advice team to grow and develop their valuable services to the international healthcare industry.”
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
